Technical Analysis for COLL - Collegium Pharmaceutical, Inc.

Grade Last Price % Change Price Change
grade D 11.63 -0.09% -0.01
COLL closed down 0.09 percent on Friday, September 20, 2019, on 1.43 times normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical COLL trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
20 DMA Support Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Doji - Bullish? Reversal 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
20 DMA Support Bullish -0.09%
20 DMA Support Bullish -0.77%
Upper Bollinger Band Touch Strength -4.12%
NR7 Range Contraction -2.60%

Older signals for COLL ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, focuses on developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its lead product candidate is Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone, a prescribed opioid medication. The company is also developing COL-172, an abuse-deterrent, extended-release oxymorphone for the treatment of chronic pain; COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of chronic pain; COL-196, a morphine formulation for the treatment of pain; and COL-171, a proprietary preclinical DETERx extended-release, abuse-deterrent methylphenidate formulation for the treatment of attention deficit hyperactivity disorder. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Canton, Massachusetts.
Pharmaceutical Diseases Pain Chemical Compounds Organic Compounds Euphoriants Chronic Pain Morphinans Platform Technology Attention Deficit Hyperactivity Disorder Ethers Opioids Phenols Hydrocodone Treatment Of Attention Deficit Hyperactivity Disorder Oxycodone Oxymorphone
Is COLL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 19.83
52 Week Low 10.01
Average Volume 264,173
200-Day Moving Average 13.9848
50-Day Moving Average 11.2404
20-Day Moving Average 11.5905
10-Day Moving Average 12.011
Average True Range 0.6706
ADX 19.34
+DI 26.193
-DI 18.5567
Chandelier Exit (Long, 3 ATRs ) 11.1032
Chandelier Exit (Short, 3 ATRs ) 12.4192
Upper Bollinger Band 12.7624
Lower Bollinger Band 10.4186
Percent B (%b) 0.52
BandWidth 20.221733
MACD Line 0.1491
MACD Signal Line 0.1518
MACD Histogram -0.0028
Fundamentals Value
Market Cap 343.86 Million
Num Shares 29.6 Million
EPS -3.59
Price-to-Earnings (P/E) Ratio -3.24
Price-to-Sales 40.60
Price-to-Book 3.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.48
Resistance 3 (R3) 12.50 12.22 12.34
Resistance 2 (R2) 12.22 12.01 12.22 12.29
Resistance 1 (R1) 11.93 11.87 11.79 11.91 12.25
Pivot Point 11.65 11.65 11.58 11.65 11.65
Support 1 (S1) 11.36 11.44 11.22 11.35 11.01
Support 2 (S2) 11.08 11.30 11.08 10.97
Support 3 (S3) 10.79 11.08 10.92
Support 4 (S4) 10.78